TSHA-103

About Taysha Gene Therapies

Taysha Gene Therapies is dedicated to eradicating monogenic CNS diseases through intrathecal delivery of gene therapies. The company has built a robust pipeline leveraging academic partnerships, most notably with UT Southwestern's Gene Therapy Program, and has advanced multiple candidates into clinical development. Following a strategic refocusing in 2023, Taysha is prioritizing its most promising assets, TSHA-102 for Rett syndrome and TSHA-120 for GAN, while seeking partnerships for earlier-stage programs. Its mission centers on addressing the high unmet need in rare neurological diseases with single-administration curative potential.

Therapeutic Areas